- Conditions
- Alzheimer Disease
- Interventions
- Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease
- Interventions
- ATH-1017
- Drug
- Lead sponsor
- LeonaBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Alzheimer's Disease
- Interventions
- KarXT, KarX-EC, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 28
- States / cities
- Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- MK-1167, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Irvine, California • Redlands, California + 25 more
- Conditions
- Alzheimer Disease
- Interventions
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos
- Drug
- Lead sponsor
- T3D Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alzheimer's Disease
- Interventions
- Rosiglitazone, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 9
- States / cities
- Litchfield Park, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 6 more
- Conditions
- Alzheimer Disease
- Interventions
- ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, octagam 10%
- Drug · Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Hoboken, New Jersey
- Conditions
- Mild-Moderate Alzheimer's Disease, Healthy Elderly
- Interventions
- MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Glendale, California • Long Beach, California • Panorama City, California + 7 more
- Conditions
- Alzheimer's Disease
- Interventions
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
- Drug
- Lead sponsor
- GemVax & Kael
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
- Conditions
- Alzheimer Disease
- Interventions
- NS 2330 (Tesofensine)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 80
- States / cities
- Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Alzheimer's Disease
- Interventions
- GC021109, Placebo
- Drug · Other
- Lead sponsor
- GliaCure, Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 5
- States / cities
- Long Beach, California • Deerfield Beach, Florida • Hallandale, Florida + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- Buntanetap/Posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 54
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases
- Interventions
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
- Conditions
- Alzheimer's Disease
- Interventions
- Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
- Drug
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- 50 Years to 88 Years
- Enrollment
- 1,331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 219
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more
- Conditions
- Alzheimer's Disease
- Interventions
- SRA-333
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- placebo, donepezil, ABT-126
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
- Conditions
- Alzheimer's Disease
- Interventions
- Albumin 5%, Albumin 20%, Immunoglobulin
- Biological
- Lead sponsor
- Instituto Grifols, S.A.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 22
- States / cities
- Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
- Conditions
- Alzheimer's Disease
- Interventions
- Idalopirdine 60 mg
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
- Conditions
- Alzheimer Disease, Dementia, Alzheimer Type
- Interventions
- E2609, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 21
- States / cities
- Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
- Conditions
- Alzheimer's Disease
- Interventions
- Bapineuzumab (AAB-001)
- Drug
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 29
- States / cities
- Peoria, Arizona • Sun City, Arizona • Encino, California + 26 more
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- CT1812, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
- Conditions
- Alzheimer's Disease
- Interventions
- FK962
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 63 more